Inflammasome biology is gaining substantial momentum as chronic inflammation is recognised as a key driver across a wide spectrum of diseases, making inflammasome pathways attractive yet challenging therapeutic targets.
Despite progress in understanding targets such as NLRP3, drug developers continue to face critical hurdles around demonstrating efficacy, selectivity, and safety early in discovery, contributing to high attrition rates.
Join Professor Luke O'Neill (Trinity College Dublin) and Dr Elise Malavasi (Associate Director of Neuroscience, Concept Life Sciences) for this webinar that explores recent advances in inflammasome science, and highlights how selecting appropriate in vitro models and meaningful readouts is essential for accurately assessing therapeutic potential.
Learning objectives:
- Explore recent developments in inflammasome drug development, with particular focus on neuroscience
- Learn how advanced in vitro assays can de-risk inflammasome-targeting programs
Presenters
Hayley Gooding
Dr. Hayley Gooding is a dedicated and enthusiastic biologist driven by the art of problem-solving and building efficient solutions. Having earned her PhD in Neuroscience from University of Edinburgh, Hayley's research provided an insight into building model systems for drug discovery and development. At Concept Life Sciences, Hayley has the privilege of leading a team of passionate scientists to deliver cutting-edge projects for the pharmaceutical and biotechnology industries.
Luke O'Neill
Professor O’Neill, FRS is a highly respected immunologist based at Trinity College Dublin, and currently the Chair of Biochemistry, with an extensive academic track record and reputation. Professor O’Neill's current research focus is in the molecular and cellular basis to inflammation and innate immunity, toll-like receptors, pro-inflammatory cytokines, signal transduction in the immune system, and immunometabolism, acknowledged in over 460 peer reviewed publications.
Elise Malavasi
Elise holds a PhD in Cellular and Molecular Basis of Disease from the University of Edinburgh and brings over 15 years of experience in neuroscience research. Her academic career focused on uncovering the molecular mechanisms underlying psychiatric illness and peripheral myelination, employing advanced cellular models and high-resolution microscopy to generate new insights into complex neurological processes.
Building on this strong academic foundation, Elise transitioned into industry, where she has applied her expertise to translational neuroscience and drug discovery. Since joining Concept Life Sciences in 2022, she has led the neuroscience team, shaping strategic direction, strengthening external collaborations, and driving scientific innovation across the service line. Elise is passionate about integrating cutting-edge cellular models and technologies to accelerate the development of new therapies for diseases of the central nervous system.
Sponsor
